| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 3.518 | 423 | 277 | 93 | 215 | 7.689 | 9.559 | 8.055 | 6.466 |
| Total Income - EUR | - | 3.518 | 423 | 277 | 93 | 215 | 7.689 | 9.559 | 8.055 | 6.466 |
| Total Expenses - EUR | - | 406 | 297 | 22 | 0 | 0 | 1.887 | 1.468 | 2.921 | 1.874 |
| Gross Profit/Loss - EUR | - | 3.112 | 126 | 256 | 93 | 215 | 5.802 | 8.090 | 5.133 | 4.592 |
| Net Profit/Loss - EUR | - | 3.007 | 113 | 247 | 90 | 209 | 5.572 | 7.871 | 4.462 | 3.894 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
Check the financial reports for the company - Neuroceli Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 819 |
| Current Assets | - | 3.068 | 3.117 | 3.303 | 3.332 | 3.484 | 9.024 | 17.141 | 14.329 | 10.771 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 0 | 2 | 0 | 0 | 0 | 3 | 3 | 582 | 1.391 |
| Cash | - | 3.068 | 3.115 | 3.303 | 3.332 | 3.484 | 9.021 | 17.138 | 13.746 | 9.380 |
| Shareholders Funds | - | 3.051 | 3.113 | 3.303 | 3.329 | 3.475 | 8.969 | 16.868 | 14.203 | 11.429 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 17 | 4 | 0 | 3 | 9 | 55 | 273 | 126 | 161 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Neuroceli Srl